Signals, Powered By EquityPandit
The US health regulator has provided its approval to Zydus Cadila for marketing fluconazole tablets that are used in the treatment of fungal infections.
The company has got the approval for Clobetasol Propionate spray that is used in the treatment of various skin disrders.
Cadila Healthcare has said in a BSE filing that “Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate spray, 0.05 percent.”
It added that the group has now more than 105 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04 fiscal.
